Copy the page URI to the clipboard
Gleadle, Pauline; Parris, Stuart; Simonetti, Roberto and Shipman, Alan
(2014).
DOI: https://doi.org/10.1016/j.cpa.2012.10.003
Abstract
In this paper we explore whether a financialisation perspective can provide a more empirically satisfying account of recent developments in the pharmaceutical industry than the more commonly used resource-based or transaction cost approaches. Specifically, we note the evolution of the pharmaceutical industry structure from giant vertically integrated firms, selling patent protected blockbuster products at premium prices, to greater vertical disintegration. Big Pharma now sources a significant volume of early stage R&D activity externally, through outright acquisitions or alliances, especially with biotechnology firms. Much of the reason for such vertical disintegration is to be found in the fundamental tension experienced between the high R&D spend necessitated by the cost of pharmaceutical innovation and declining returns on this expenditure in terms generating new product sales and FDA approval rates, which have remained broadly constant at an average of 20-35 approvals per year. The new R&D outsourcing strategy has not delivered an increase in marketable drug discoveries or new ‘blockbuster’ profits. Instead, shareholder returns have been maintained through Big Pharma’s decision to distribute cash back to shareholders via share buybacks and dividends (as advocated by Jensen). Thus we conclude that such developments within Big Pharma worldwide are best explained through the lens of a financialisation, as opposed to a resource-based or transaction cost framework.
Viewing alternatives
Download history
Metrics
Public Attention
Altmetrics from AltmetricNumber of Citations
Citations from DimensionsItem Actions
Export
About
- Item ORO ID
- 36043
- Item Type
- Journal Item
- ISSN
- 1045-2354
- Extra Information
- Special issue: Critical accounts and perspectives on financialization
- Keywords
- financialisation; Big Pharma; biotech firms; resource-based frameworks; transaction cost frameworks
- Academic Unit or School
-
Faculty of Arts and Social Sciences (FASS) > Social Sciences and Global Studies > Economics
Faculty of Arts and Social Sciences (FASS) > Social Sciences and Global Studies
Faculty of Arts and Social Sciences (FASS) - Research Group
-
?? idii ??
Innovation, Knowledge & Development research centre (IKD)
Institute for Innovation Generation in the Life Sciences (Innogen) - Copyright Holders
- © 2013 Elsevier Ltd
- Depositing User
- Alan Shipman